Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 9 hours ago

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m.

GlobeNewsWire • Oct 8, 2026

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

Zacks Investment Research • Oct 6, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.

Zacks Investment Research • Oct 2, 2026

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% YoY, with strong payer coverage and operational leverage emerging. AGIO's $965M cash position supports pipeline expansion and mitigates near-term dilution risk ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.

Seeking Alpha • Aug 20, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • Aug 13, 2026

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

Zacks Investment Research • Jul 31, 2026

Agios Pharmaceuticals Q2 Earnings Call Highlights

Agios Pharmaceuticals NASDAQ: AGIO reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease approval later this year.

MarketBeat • Jul 30, 2026

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026 sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026 Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera $964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well capitalized to support commercial execution and pipeline advancement CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2026.

GlobeNewsWire • Jul 30, 2026